Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction

AIDS

Volumn 19, Issue 15, 2005, Pages 1635-1641

  Friedland, Gerald ^a   Andrews, Laurie ^a   Schreibman, Tanya ^a   Agarwala, Sangeeta ^c   Daley, Leith ^a   Child, Michael ^c   Shi, Julia ^b   Wang, Yonghua ^c   O'Mara, Edward ^c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b APT Foundation Drug Treatment Program ^*  (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

Antiretroviral therapy; Atazanavir; Drug interactions; Methadone; Substance abuse therapy

Indexed keywords

ATAZANAVIR; CYTOCHROME P450 3A4; METHADONE; PROTEINASE INHIBITOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; STEADY STATE; WITHDRAWAL SYNDROME;

EID: 27144449749     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000183628.20041.f2     Document Type: Article

References (35)

1. UNAIDS. The changing HIV/AIDS epidemic in Europe and Central Asia. Joint United Nations Programme on HIV/AIDS. Geneva: UNAIDS; 2004. Accessed 11 February 2004 www.unaids.org.
2. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000; 133:40-54.
3. Friedland GH. HIV Disease in substance abusers: treatment issues. In: The Medical Management of AIDS, 6th edn. Edited by Sande MA, Volberding P. Philadelphia: Saunders; 1999. pp. 575-591.
4. Kristensen K, Christensen CB, Christrup LL. The Mu1, Mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995; 56:45-60.
5. Scott CC, Robins EB, Chen KK. Pharmacologic comparison of the optical isomers of methadone. J Pharmacol Exp Ther 1998; 93:282-286.
6. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, et al. Involvement of cytochrome P450 3A4 enzyme in the N-methylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9:365-373.
7. Schwartz EL, Brechbühl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infections. J Acquir Immune Defic Syndr 1992; 5:619-626.
8. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr 1998; 18:435-443.
9. Rainey PM, Friedland GH, McCance EF, Andrews L, Mitchell SM, Charles C, et al. Interaction of methadone with didanosine (ddl) and stavudine (d4T). J Acquir Immune Defic Syndr 2000; 24:241-248.
10. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13:957-962.
11. Clarke SM, Mulcahy F, Tjia J, Reynolds HE, Gibbons SE, Barry MG, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001; 33:1595-1597.
12. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001; 51:213-217.
13. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy 2000; 20 (1):93-94.
14. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr 2001; 27:153-160.
15. Bart PA, Rizzardi PG, Gallant S, Golay KP, Baumann P, Pantaleo G, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 2001; 23:553-555.
16. McCance-Katz EF, Farber S, Selwyn PA, O'Connor A. Decrease in methadone levels with nelfinavir mesylate. Am J Psychiatry 2000; 157:481.
17. Hsyu PH, Lillibridge JH, Maroldo L, Weiss WR, Kerr BM. Pharmacokinetic and pharmacodynamic interactions between nelfinavir and methadone. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January 2000 [abstract 87].
18. McCance-Katz EF, Rainey P, Morse G, Morse G, Friedland G, Gourevitch M, et al. Drug interactions between opioids and antiretroviral medications, interaction between methadone, LAAM, and nelfinavir. Am J Addict 2004; 13:163-180.
19. McCance-Katz EF, Rainey P, Friedland G, Jatlow P. The protease inhibitor Kaletra (lopinavir-ritonavir) may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003; 37:476-482.
20. Havlir DV, O'Marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 2004; 38:1599-1604.
21. Handlesman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13:293-308.
22. Liang HR, Foltz RL, Meng M, Bennett P. Method development and validation for quantitative determination of methadone enantiomers in human plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 806:191-198.
23. Schuster S, Burzawa M, Jemal E, Loizillon P, Couerbe D, Whigan A. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 788:377-386.
24. Bristol- Meyers Squibb. Reyataz. [Package Insert] Princeton, NJ: Bristol- Meyers Squibb; July 2004.
25. Center for Biologics Evaluation Research. Guidance for Industry, In vivo Drug Metabolism/Interaction Studies, Study Design, Data Analysis and Recommendations for Dosing and Labeling. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation Research; 1999. www.fda.cber/ guidelines/htm.
26. Ena J, Pasuau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis 2003; 36:1186-1190.
27. Rosenbach KA, Allison R, Nadler JP. Daily dosing of highly active antiretroviral therapy. Clin Infect Dis 2002; 34:686-692.
28. Gourevitch MN, Friedland G. Interactions between methadone and medications used to treat HIV infection. Mt Sinai J Med 2000; 67:429-436.
29. Foster DJR, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R) and (S) methadone in methadone maintenance patients. Br J Clin Pharmacol 2000; 50:427-440.
30. Cantilena L, McCrea J, Blazes D, Winchell G, Carides A, Royce C, et al. Lack of a pharmacokinetic interaction between indinavir and methadone. Clin Pharmacol Ther 1999; 65:135.
31. Hendrix CW, Wakeford J, Wire MB, Lou Y, Bigelow GE, Martinez E, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy 2004; 24:1110-1121.
32. GlaxoSmithKline. Agenerase (amprenavir). [Product information] Research Triangle Park, NC: GlaxoSmithKline; 1999.
33. Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry M, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2002; 34:1143-1145.
34. Stevens RC, Rapaport S, Maroldo-Connelly L, Patterson JB, Bertz R. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J Acquire Immune Defic Syndr 2003; 33:650-651.
35. Beauverie P, Taburet AM, Dessalles MC, Furlan V, Touzeau D. Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. AIDS 1998; 12:2510-2511.